Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, including a system for providing treatment suggestions. The system includes a data warehouse including patient data for a plurality of patients associated with one or more care facilities, and one or more processors including instructions for implementing an evidence-based clinical decision engine. The engine is operable to: identify patient cohorts defined by the data in the data warehouse including identifying relevant cohorts that include a population of patients who are similar, both by phenotype and genotype, to a candidate patient; evaluate the patient cohorts to identify a cohort that is a best match for the candidate patient based on historical treatment information for patients in each candidate patient cohort; select a cohort from the plurality of cohorts; and provide a treatment suggestion to the patient or a care provider based on the selection.

Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Abstract: The subject invention pertains to compositions and methods for treatment of malignancies and inhibiting the growth of cancer cells, such as multiple myeloma and other hematologic malignancies, using HYD1 peptides. Other aspects of the invention are directed to methods for selection of agents useful in the treatment of malignancies and inhibiting the growth of cancer cells. Further aspects of the invention include methods for determining whether a cancer is sensitive or resistant to treatment with HYD1 peptides based on the presence of certain biomarkers, such as ?4 integrin and CD44 expression.

Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Abstract: The subject invention pertains to materials and methods for treating oncological disorders. The subject invention also pertains to materials and methods for preventing or reducing the development by cancer cells of resistance to an anticancer therapy, such as chemotherapy, radiotherapy and/or immunotherapy. In one embodiment, a patient is treated with an agent that inhibits cholesterol synthesis or that prevents or reduces the increase in cholesterol synthesis observed in therapy-resistant cancer cells. In another embodiment, a patient is treated with an agent that increases the expression, activity, or amount of a Bim protein in a cell. In another embodiment, a patient is treated with an agent to inhibit or reduce cancer cell adhesion to extracellular matrices or stromal cells. In another embodiment, a patient is treated with an agent to inhibit expression of a gene of function of a protein of the FANC/BRCA pathway.

Abstract: Systems and methods are provided including a system for managing patient data. The system includes a computing system including a processing unit and a storage. The processing unit executes one or more programs for managing patient data. Managing patient data includes enrolling patients in a centralized care network including presenting each patient with an electronic enrollment interface, assigning each patient a patient identifier, and receiving an electronic consent to collect data. Managing patient data further includes providing patient data to the centralized care network including patient data relating to disease progression, clinical trials and treatments rendered.

Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects.

Abstract: The invention provides a computer network comprising a first computer and one or more second computers that are in electronic communication with each other. The first computer is associated with a first health care facility and has instructions for retrieving, over a network, one or more data structures for a patient enrolled in a health care program. The one or more data structures for the patient collectively comprise (i) a patient identifier, (ii) a molecular profile from a biological specimen obtained from the patient at the first health care facility; and (iii) a clinical characterization of the patient that was made at the first health care facility. The first computer has instructions for retrieving, over the network connection, one or a plurality of treatment regimens that are deemed suitable for the patient based upon the molecular profile and the clinical characterization of the patient.

Abstract: Systems and methods including a computer network are provided. The computer network includes a plurality of affiliate computing systems, each affiliate computing system including a processing unit and storage, the processing unit executing one or more programs for supporting care of a patient. The computer network includes a centralized care network including a central health care computing system, the central health care computing system being coupled to each affiliate computing system by way of a network and including a processing unit and storage, the processing unit executing one or more programs for managing patient records stored in the storage.

Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects.

Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects.

Abstract: Systems and methods are provided including a system for managing patient data. The system includes a computing system including a processing unit and a storage. The processing unit executes one or more programs for managing patient data. Managing patient data includes enrolling patients in a centralized care network including presenting each patient with an electronic enrollment interface, assigning each patient a patient identifier, and receiving an electronic consent to collect data. Managing patient data further includes providing patient data to the centralized care network including patient data relating to disease progression, clinical trials and treatments rendered.

Abstract: Systems and methods including a computer network are provided. The computer network includes a plurality of affiliate computing systems, each affiliate computing system including a processing unit and storage, the processing unit executing one or more programs for supporting care of a patient. The computer network includes a centralized care network including a central health care computing system, the central health care computing system being coupled to each affiliate computing system by way of a network and including a processing unit and storage, the processing unit executing one or more programs for managing patient records stored in the storage.

Abstract: Personalized health information is provided by maintaining a patient profile over time and matching information from the patient profile to appropriate patient-centric information related to that patient's specific medical condition. The patient profile can include a variety of medical information. The patient profile is matched, for example, to patient-centric options for care, clinical trials for which the patient is eligible, drug treatment regimens directly related to each patient's specific condition, scheduling of the treatments, survivorship plans and data, information about managing symptoms, nutritional information, rehabilitation recommendations, possible adverse events based on specific treatments to monitor, and personalized education and information. The patient profile can be populated with information from a database, such as one associated with a cancer registry.

Abstract: The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds ?1 integrin to a patient in need thereof. In one embodiment, the ?1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof.

Abstract: Peptides and methods of their use for inhibiting drug and radiation-therapy resistance in cancerous cells in which efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by administration of an effective amount of a peptide that inhibits cell adhesion mediated drug resistance (CAM-DR). Preferably, the peptide comprises D-amino acids having the sequence: kmviywkag (RZ-3) or is a variant or modified version thereof. The peptide is preferably administered to the patient prior to chemotherapy and/or radiation therapy. Inhibition of cell adhesion mediated drug resistance (CAM-DR) by RZ-3 in multiple myeloma cells is disclosed.